Briskey David, Tucker Patrick, Johnson David W, Coombes Jeff S
School of Human Movement and Nutrition Sciences, University of Queensland, St Lucia, QLD, Australia.
Clinical Biochemistry Laboratory, Central Queensland University, Rockhampton, Australia.
Clin Exp Nephrol. 2017 Feb;21(1):7-15. doi: 10.1007/s10157-016-1255-y. Epub 2016 Mar 10.
It is well-established that uremic toxins are positively correlated with the risk of developing chronic kidney disease and cardiovascular disease. In addition, emerging data suggest that gut bacteria exert an influence over both the production of uremic toxins and the development of chronic kidney disease. As such, modifying the gut microbiota may have the potential as a treatment for chronic kidney disease. This is supported by data that suggest that rescuing microbiota dysbiosis may: reduce uremic toxin production; prevent toxins and pathogens from crossing the intestinal barrier; and, reduce gastrointestinal tract transit time allowing nutrients to reach the microbiota in the distal portion of the gastrointestinal tract. Despite emerging literature, the gut-kidney axis has yet to be fully explored. A special focus should be placed on examining clinically translatable strategies that might encourage improvements to the microbiome, thereby potentially reducing the risk of the development of chronic kidney disease. This review aims to present an overview of literature linking changes to the gastrointestinal tract with microbiota dysbiosis and the development and progression of chronic kidney disease.
众所周知，尿毒症毒素与慢性肾脏病和心血管疾病的发生风险呈正相关。此外，新出现的数据表明，肠道细菌对尿毒症毒素的产生和慢性肾脏病的发展均有影响。因此，调节肠道微生物群可能具有作为慢性肾脏病治疗方法的潜力。这得到了一些数据的支持，这些数据表明挽救微生物群失调可能：减少尿毒症毒素的产生；防止毒素和病原体穿过肠道屏障；以及减少胃肠道转运时间，使营养物质能够到达胃肠道远端的微生物群。尽管有新出现的文献，但肠-肾轴尚未得到充分探索。应特别关注研究可能促进微生物群改善从而潜在降低慢性肾脏病发生风险的临床可转化策略。本综述旨在概述将胃肠道变化与微生物群失调以及慢性肾脏病的发生和进展联系起来的文献。
